ARTICLE | Company News

Daiichi, Inovalon exploring abuse-deterrent opioid outcomes

September 21, 2017 10:00 PM UTC

Daiichi Sankyo Co. Ltd. (Tokyo:4568) partnered with Inovalon Holdings Inc. (NASDAQ:INOV) to use Inovalon’s MORE2 Registry and Inovalon ONE platform to identify outcomes for abuse-deterrent opioids that would be valuable to health plans and then design outcomes-based contracts based on their findings. Inovalon declined to provide financial terms.

The Medical Outcomes Research for Effectiveness and Economics (MORE2) Registry houses longitudinal demographic and medical data from 230 million patients. The Inovalon ONE cloud-based platform combines more than 70 data tool sets including technologies for data integrity analysis, predictive analysis, clinical data optical character recognition, natural language processing, decision support and large-scale transactional computation. Dan Mendelson, President of Inovalon’s Avalere Health LLC subsidiary, told BioCentury that the company’s analysis will seek to determine the outcomes which would be the “most compelling” to health plan providers...